[Kangzhi Pharmaceutical: Received Notice of Case Filing from the China Securities Regulatory Commission] On September 18, Kangzhi Pharmaceutical (300086.SZ) announced that the company had received a "Notice of Case Filing" issued by the China Securities Regulatory Commission. The China Securities Regulatory Commission decided to file a case against the company due to suspected violations of information disclosure laws and regulations. As of the date of the announcement, the company's production and operation activities are carried out normally, and the above matters will not have a significant impact on normal production and operations. During the investigation period, the company will actively cooperate with the China Securities Regulatory Commission and fulfill its information disclosure obligations.